FDA 483 - CSL Behring GmbH - March 04, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of CSL Behring GmbH in Marburg, Germany, a licensed biological drug manufacturer, revealed significant deficiencies. The firm failed to adequately investigate product discrepancies and complaints, including mold and yeast contamination, and lacked sufficient rationale for not investigating retention samples. Furthermore, the facility exhibited poor maintenance with recurring insect infestations, and procedures to prevent microbiological contamination of sterile drug products were found to be insufficient, along with inadequate cleaning validations and issues with vial crimping.
ID · 45772e3f-dea9-45ad-b478-23cd419f7dbe